MaxCyte Inc

MXCT

Company Profile

  • Business description

    MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

  • Contact

    9713 Key West Avenue
    Suite 400
    RockvilleMD20850
    USA

    T: +1 301 944-1700

    E: [email protected]

    https://www.maxcyte.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2025

    Employees

    114

Stocks News & Analysis

stocks

Going into earnings, is Tesla stock a buy, a sell, or fairly valued?

Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
stocks

Why I dislike dividend stocks

If you need income then buying dividend stocks makes perfect sense. But if you don’t then it makes little sense because it’s likely to limit building real wealth. Here’s what you should do instead.
stocks

Chart of the Week: Ramsay Health Care margins to rebound

Charts from our latest stock pitch for Ramsay Health Care show a clear path to improved profitability.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,293.2045.10-0.48%
CAC 408,174.2014.39-0.18%
DAX 4023,830.99441.20-1.82%
Dow JONES (US)46,190.61238.370.52%
FTSE 1009,354.5781.52-0.86%
HKSE25,247.10641.41-2.48%
NASDAQ22,679.97117.440.52%
Nikkei 22547,582.15695.59-1.44%
NZX 50 Index13,289.2199.89-0.75%
S&P 5006,664.0134.940.53%
S&P/ASX 2008,995.3034.70-0.38%
SSE Composite Index3,839.7676.47-1.95%

Market Movers